Starpharma Holdings Ltd
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurr… Read more
Starpharma Holdings Ltd (SPHRY) - Total Liabilities
Latest total liabilities as of June 2025: $6.42 Million USD
Based on the latest financial reports, Starpharma Holdings Ltd (SPHRY) has total liabilities worth $6.42 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Starpharma Holdings Ltd - Total Liabilities Trend (2014–2025)
This chart illustrates how Starpharma Holdings Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Starpharma Holdings Ltd Competitors by Total Liabilities
The table below lists competitors of Starpharma Holdings Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
First Capital Inc
NASDAQ:FCAP
|
USA | $1.10 Billion |
|
TaTaTu SpA
PA:ALTTU
|
France | €48.74 Million |
|
Stratus Properties Inc
NASDAQ:STRS
|
USA | $240.48 Million |
|
d'Amico International Shipping S.A
OTCQX:DMCOF
|
USA | $270.93 Million |
|
Suzhou Iron Technology Co. Ltd. A
SHG:688329
|
China | CN¥591.31 Million |
|
Power Solutions International Inc
PINK:PSIX
|
USA | $297.03 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Starpharma Holdings Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Starpharma Holdings Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Starpharma Holdings Ltd (2014–2025)
The table below shows the annual total liabilities of Starpharma Holdings Ltd from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $6.42 Million | -26.16% |
| 2024-06-30 | $8.70 Million | -49.64% |
| 2023-06-30 | $17.27 Million | -2.87% |
| 2022-06-30 | $17.78 Million | +62.57% |
| 2021-06-30 | $10.94 Million | +41.10% |
| 2020-06-30 | $7.75 Million | +19.93% |
| 2019-06-30 | $6.46 Million | +23.50% |
| 2018-06-30 | $5.23 Million | -6.65% |
| 2017-06-30 | $5.61 Million | -41.68% |
| 2016-06-30 | $9.62 Million | +26.50% |
| 2015-06-30 | $7.60 Million | +94.35% |
| 2014-06-30 | $3.91 Million | -- |